{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:56:45Z","timestamp":1769583405817,"version":"3.49.0"},"reference-count":12,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[1999,3,1]],"date-time":"1999-03-01T00:00:00Z","timestamp":920246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Diagn Lab Immunol"],"published-print":{"date-parts":[[1999,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Diagnosis of acute Q fever is usually confirmed by serology, on the basis of anti-phase II antigen immunoglobulin M (IgM) titers of \u22651:50 and IgG titers of \u22651:200. Phase I antibodies, especially IgG and IgA, are predominant in chronic forms of the disease. However, between January 1982 and June 1998, we observed anti-phase II antigen IgA titers of \u22651:200 as the sole or main antibody response in 10 of 1,034 (0.96%) patients with acute Q fever for whom information was available. In order to determine whether specific epidemiological or clinical factors were associated with these serological profiles, we conducted a retrospective case-control study that included completion of a standardized questionnaire, which was given to 40 matched controls who also suffered from acute Q fever. The mean age of patients with elevated phase II IgA titers was significantly higher than that usually observed for patients with acute Q fever (\n            <jats:italic>P<\/jats:italic>\n            = 0.026); the patients were also more likely than controls to live in rural areas (\n            <jats:italic>P<\/jats:italic>\n            = 0.026) and to have increased levels of transaminase in blood (\n            <jats:italic>P<\/jats:italic>\n            = 0.03). Elevated IgA titers are usually associated with chronic Q fever and are directed mainly at phase I antigens. Although the significance of our findings is unexplained, we herein emphasize the fact that IgA antibodies are not specific for chronic forms of Q fever and that they may occasionally be observed in patients with acute disease. Moreover, as such antibody profiles may not be determined by most laboratories, which test only for total antibody titers to phase I and II antigens, the three isotype-specific Ig titers should be determined as the first step in diagnosing Q fever.\n          <\/jats:p>","DOI":"10.1128\/cdli.6.2.173-177.1999","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T19:22:06Z","timestamp":1577820126000},"page":"173-177","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":5,"title":["Predominant Immunoglobulin A Response to Phase II Antigen of\n            <i>Coxiella burnetii<\/i>\n            in Acute Q Fever"],"prefix":"10.1128","volume":"6","author":[{"given":"Pierre-Edouard","family":"Fournier","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Unite\u0301 des Rickettsies, CNRS: UPRESA 6020, Faculte\u0301 de Me\u0301decine, Universite\u0301 de la Me\u0301diterrane\u0301e, 13385 Marseille Cedex 05, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Raoult","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Unite\u0301 des Rickettsies, CNRS: UPRESA 6020, Faculte\u0301 de Me\u0301decine, Universite\u0301 de la Me\u0301diterrane\u0301e, 13385 Marseille Cedex 05, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1993.00410050074010"},{"key":"e_1_3_1_3_2","unstructured":"Dean\nA. G.\nDean\nJ. A.\nBurton\nA. H.\nDicker\nR. C.\nEpi Info version 5: a word processing database and statistics program for epidemiology on microcomputers.\n1990\nCenters for Disease Control and Prevention\nAtlanta Ga"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.22.4.484-487.1985"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/10520296409061219"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.39.2.977-981.1983"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.41.3.1089-1098.1983"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/155.3.570"},{"key":"e_1_3_1_9_2","unstructured":"Raoult D. P. Houpikian H. Tissot-Dupont J. M. Riss J. Arditi-Djiane and P. Brouqui. Treatment of Q fever endocarditis: comparison of two regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch. Intern. Med. in press."},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/142.2.250"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90173-9"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.1.2.189-196.1994"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-19-3-281"}],"container-title":["Clinical Diagnostic Laboratory Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CDLI.6.2.173-177.1999","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CDLI.6.2.173-177.1999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T03:50:40Z","timestamp":1645588240000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CDLI.6.2.173-177.1999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,3]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1999,3]]}},"alternative-id":["10.1128\/CDLI.6.2.173-177.1999"],"URL":"https:\/\/doi.org\/10.1128\/cdli.6.2.173-177.1999","relation":{},"ISSN":["1071-412X","1098-6588"],"issn-type":[{"value":"1071-412X","type":"print"},{"value":"1098-6588","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,3]]},"assertion":[{"value":"1998-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-12-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}